Rating Alert: UDG Healthcare PLC (LON:UDG) “Buy” Rating Reconfirmed at N+1 Singer; The Price Target is GBX 746.00

November 24, 2016 - By whatsonthorold

UDG Healthcare PLC (LON:UDG) Rating

Stock analysts at N+1 Singer have GBX 746.00 price target on UDG Healthcare PLC (LON:UDG). N+1 Singer’s price target suggests a potential upside of 19.03% from the company’s last stock close price. The rating was shown in analysts note on Thursday morning.

Udg Healthcare PLC (LON:UDG) Ratings Coverage

Out of 9 analysts covering UDG Healthcare PLC (LON:UDG), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. GBX 750 is the highest target while GBX 5.15 is the lowest. The GBX 679.29 average target is 8.60% above today’s (GBX 625.5) stock price. UDG Healthcare PLC has been the topic of 42 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Goodbody on Thursday, August 4. The firm has “Buy” rating given on Thursday, May 19 by Goodbody. Cantor Fitzgerald maintained the shares of UDG in a report on Friday, April 1 with “Buy” rating. As per Wednesday, May 25, the company rating was maintained by Berenberg. As per Friday, October 16, the company rating was maintained by Berenberg. The firm has “Outperform” rating given on Thursday, November 19 by Davy Research. The rating was maintained by Jefferies on Friday, September 30 with “Buy”. The rating was maintained by Davy Research on Monday, October 24 with “Outperform”. The company was maintained on Wednesday, September 28 by Stifel Nicolaus. The firm has “Outperform” rating by Davy Research given on Thursday, August 4.

About 565,294 shares traded hands or 9.94% up from the average. Udg Healthcare PLC (LON:UDG) has risen 9.66% since April 26, 2016 and is uptrending. It has outperformed by 4.25% the S&P500.

UDG Healthcare plc, formerly United Drug plc, is a healthcare services well-known provider in the Republic of Ireland, the United Kingdom, North America and Continental Europe. The company has a market cap of 1.53 billion GBP. The Firm operates in three divisions. It has a 33.61 P/E ratio. The Ashfield Commercial & Medical Services segment is engaged in the provision of sales, marketing and healthcare communications services to pharmaceutical companies, and it also provides sales teams, healthcare communications, telesales, nurse educators, medical information, pharmacovigilance, regulatory and event management services to over 300 healthcare companies in approximately 20 countries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>